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Abstract
Background: The life course accumulation of overt and subclinical myocardial dysfunction contributes to older age
mortality, frailty, disability and loss of independence. The Medical Research Council National Survey of Health and
Development (NSHD) is the world’s longest running continued surveillance birth cohort providing a unique oppor‑
tunity to understand life course determinants of myocardial dysfunction as part of MyoFit46–the cardiac sub-study of
the NSHD.
Methods: We aim to recruit 550 NSHD participants of approximately 75 years+ to undertake high-density surface
electrocardiographic imaging (ECGI) and stress perfusion cardiovascular magnetic resonance (CMR). Through com‑
prehensive myocardial tissue characterization and 4-dimensional flow we hope to better understand the burden of
clinical and subclinical cardiovascular disease. Supercomputers will be used to combine the multi-scale ECGI and CMR
datasets per participant. Rarely available, prospectively collected whole-of-life data on exposures, traditional risk fac‑
tors and multimorbidity will be studied to identify risk trajectories, critical change periods, mediators and cumulative
impacts on the myocardium.
Discussion: By combining well curated, prospectively acquired longitudinal data of the NSHD with novel CMR–ECGI
data and sharing these results and associated pipelines with the CMR community, MyoFit46 seeks to transform our
understanding of how early, mid and later-life risk factor trajectories interact to determine the state of cardiovascular
health in older age.
Trial registration: Prospectively registered on ClinicalTrials.gov with trial ID: 19/LO/1774 Multimorbidity Life-Course
Approach to Myocardial Health- A Cardiac Sub-Study of the MCRC National Survey of Health and Development
(NSHD).

*Correspondence: gabriella.captur@ucl.ac.uk
2
Institute of Cardiovascular Science, University College London, Huntley
Street, London WC1E 6DD, UK
Full list of author information is available at the end of the article
© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which
permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the
original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or
other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line
to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this
licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativeco
mmons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Webber et al. BMC Cardiovascular Disorders

(2022) 22:140

Page 2 of 17

Keywords: Subclinical myocardial dysfunction, Cardiovascular health, Life course risk factors, Risk trajectories,
Cardiovascular magnetic resonance, Electrocardiographic imaging, Myocardial tissue characterization, Perfusion,
4-dimensional flow

Background
Unprecedented numbers of people are now surviving
into older age [1, 2] which means that the global trends
for cardiovascular disease (CVD) prevalence will continue to increase, further adding to the burden of disease [3]. Improving our understanding of the causes of
CVD is crucial to developing lifestyle or pharmacological interventions that can either prevent or delay the
onset of disease.
The progressive structural, functional and hemodynamic changes affecting the myocardium as a result of
ageing, lead to mortality, morbidity, disability and loss of
independence in later life [4, 5]. Risk factors for cardiometabolic disease impact the heart from early childhood
[6, 7] and with advancing age, the health of the myocardium is progressively compromised by overt stepwise and
subclinical cumulative injury [5]. It is currently unclear
how the age-dependent influences of multimorbidity, or
the effect of early-life exposures, influence the various
pathophysiological processes that lead to cardiac disease
[8]. Prospectively collected data across the whole life
course are required to address these research questions.
The Medical Research Council (MRC) National Survey of Health and Development (NSHD) is the longest
running continuous study of human development in the
world, which started as an English, Scottish and Welsh
representative sample of 5,362 participants, born in one
week in 1946 [9–12]. Repeated data collection waves
since birth have provided detailed information on earlylife exposures, traditional cardiometabolic risk factors
and emergent multimorbidity [9, 11]. With members now
aged ≥ 75, it is an opportune time to perform advanced
cardiac phenotyping to understand which life course
trajectories are conducive to the preservation of cardiovascular longevity. We propose to combine high spatial
and temporal resolution electrocardiographic imaging
(ECGI) and cardiovascular magnetic resonance (CMR)
techniques to study the structure, function, electrophysiology (EP) and hemodynamics of the whole heart and
correlate this information with the rich life course data
that the NSHD cohort provides.
We describe here the research protocol of ‘MyoFit46’,
a prospective longitudinal sub-study of 550 NSHD
study members which is set to run for a total of 5 years.
We summarize the study’s organization, funding,
design, participant inclusion criteria, data sharing policy and analysis strategy.

Methods
Study organization

This prospective longitudinal NSHD sub-study will
take place at the University College London (UCL)
Bloomsbury Centre for Clinical Phenotyping in central London. MyoFit46 is funded by the British Heart
Foundation (BHF) special project grant (to G.C.
SP/20/2/34841) and supported by the MRC (MC UU
00019/1).
Separate ethical approval for the main NSHD study
has been provided by Research Ethics Committees
(REC) in England and Scotland as outlined in previous
papers [9, 10, 13]. Ethical approval for this study was
granted by the London Queen Square REC (REC: 19/
LO/1774. London REC—Queen Square, IRAS: 254776).
All participants will provide written informed consent
to participate in the study and for their study data to be
stored electronically in accordance with the Data Protection Act (2018) as laid out by the legal requirements
of the General Data Protection Regulation (GDPR).
Participants

Entry criteria to the study are based on maximizing the life course data available for analysis. We will
recruit 550 NSHD participants, some of which have
been recruited to other recent sub-studies [12] and
who have not previously withdrawn, died, or remained
untraced from the main study by age 70. Participants
will have a rich life course data set available having
participated in the majority of data collection sweeps
(Table 1). The NSHD is a representative sample of 5362
males and females born in the UK in March 1946 originally intended to answer questions on fertility rates
and obstetric servives [14]. At the 2014–2016 NSHD
data sweep we obtained data on surviving study members that lived in Britain and with whom we still had
contact [14], which has provided us with 2502 participants potentially available to invite for examination.
The first 550 study members fulfilling these criteria and
providing written consent will be included. Excluded
individuals will be those with contraindications to contrast perfusion CMR, including but not limited to those
with permanent implantable cardiac electronic devices,
claustrophobia, renal failure, severe asthma or known
trifascicular or higher degree conduction block on their
resting surface 12-lead ECG.

Neurological function

Cardiovascular function

Health/physical measures

Social factors
✓

✓

Education
✓

–
–
–
–
–
–
–

Anthropometric measures
Smoking status
Physical health
Diet
Respiratory function
Musculoskeletal function
Blood samples
Urine samples
–
–
–
–
–
–
–

HR variability
12 lead ECG
Echocardiogram
Ambulatory blood pressure
Cardiac MRI
Brain MRI
Cognitive function

Morbidity and mortality

–

–

–

–

–

–

–

–

–

–

–

✓
–

✓
–

–

–

–

–

–

–
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–

–

–
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✓

✓

✓

✓

✓

✓

8
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–

–

–

–

–

–

–

–

–

–

✓

–

–

✓

✓

✓

–

✓

✓

–

✓

–

–
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–

–

✓
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✓

2

1

8

1947–1950 1951–1960
(1–4 y)
(5–15 y)

1946 (birth)

Data collection year range (age, years)

✓
–

–

–

–

–

–

–

✓

✓

✓

✓

✓

✓

✓

–

✓

✓

✓

3

1978–2003
(32–57 y)

✓

✓

ECG, Electrocardiogram; HR, heart rate; MRI, magnetic resonance imaging; NSHD, National Survey of Health and Development; y, years

✓

–

–
–

✓

✓

✓

–

✓

✓

✓

✓

✓

✓

✓

✓

–

✓

✓

✓

1

2014–2015
(68–69 y)

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

–

✓

✓

✓

1

2006–2010
(60–64 y)

Participants recruited to MyoFit46 may not necessarily have participated in all the data sweeps outlined in this table, but they will have participated in the majority of sweeps

Measurement

Data collections

Table 1 Summary of the various data collection sweeps so far undertaken on NSHD cohort participants over time
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Study outline

All participants meeting the inclusion criteria will be
invited to take part through an invitation letter and following verbal agreement, a suitable date/time for the
CMR scan will be booked and transport arranged to
and from the study center. In light of the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2)
global pandemic specific measures will be implemented
to minimize the risk of participant/investigator infection or transmission throughout the study period in
accordance with changing government guidelines.
A flowchart outlining the study protocol is shown in
Fig. 1.
Assessment and management of risk

A duty-of-care protocol based on the NSHD protocol used previously, in accordance with the MRC/Wellcome Trust guidelines [15] will be implemented for the
purposes of feeding back health-related findings from
the study. All baseline measurements will be routinely
reported to the general practitioner with a copy also
being sent to the participant.
All CMR images will be pre-reported by a cardiology clinical research fellow and finalized by a consultant cardiologist. Any extra-cardiac findings considered
to be clinically significant will be secondarily reported
by a consultant radiologist at University College London
National Health Service (NHS) Foundation Trust. The
study follows guidelines based on the UK Biobank imaging study [16] and CMR information is only reported
back to the GP in the case that an abnormality is considered medically actionable. A non-exhaustive list of
potential CMR findings considered reportable are summarized in Table 2.
All serious unexpected study-related adverse events
will be reported immediately according to standard operating procedures for research studies carried out at UCL.
Data handling and management

All data will be handled in accordance with the UK DPA
2018 as laid out by the UK GDPR. All clinical data will
be pseudonymized by tokenization and will not bear the
participant’s name or other directly identifiable data.
The participant’s study identification number only, will
be used for identification. All participant information
including pre-screening questionnaires, relevant medical history, anthropometric measurements, baseline
ECG and CMR data points will be imported into the
secure research electronic data capture project (REDCap V.7.3.2) controlled by the principal investigator and
accessible to named research assistants.
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Study protocol description
Blood and urine specimen collection and storage

Blood samples will be collected and stored for future biomarker analysis. Two 4.0 ml ethylenediaminetetraacetic
acid and two clotted 3.5 ml serum-separating tube whole
blood samples will be collected. All tubes will be spun at
1300 g for 20 min at room temperature to generate supernatant (plasma), buffy coat and red blood cells which will
be individually aliquoted into 1 ml, polypropylene, cryovials and stored at – 80 °C, for later analysis. One 10.5 ml
PAXgene DNA tube and one 9.4 ml PAXgene RNA tube
will be collected and stored upright for 24 h at – 20 °C,
and then transferred to – 80 °C, for future analysis. Pointof-care testing will be carried out for creatinine using the
StatSensor Xpress Creatinine monitor (Nova Biomedical,
USA) and hemoglobin using HemoCue Hb 801 monitor
(HemoCue AB, Sweden) that also permits derivation of
hematocrit. A random urine sample will be collected by
the participant in a polypropylene universal container
and aliquoted into slender conical tubes for storage at
– 80 °C.
Baseline measurements

Height and weight will be measured according to standardized protocols previously described [12]. Bioimpedance body composition measurements (TANITA
Cooperation, Japan) will also be recorded. Lying, sitting
and 3-min standing blood pressure (BP) will be measured
(OMROM MIT ELITE PLUS; OMRON Healthcare UK
Ltd. Milton Keynes) on the left arm over 3 acquisitions. A
resting 12-lead surface ECG will be recorded using a PC
based ECG monitor (Cardioperfect Workstation; Welch
Allyn, New York. USA). Resting heart rate (HR) variability will be assessed immediately after the standard ECG
using the same lead positions for a total of 5 min.
Electrocardiographic imaging (ECGI)

ECGI is the process of combining heart and torso geometry with multiple body surface potentials to generate
epicardial electrograms and panoramic maps of cardiac
excitation [17–19]. ECGI has been extensively validated
in ex vivo animal studies using a torso-tank experimental
method [20, 21] and in vivo animal experiments. It has
also been shown to accurately correlate with invasive EP
mapping in ventricular tachycardia (VT) [22], it has been
validated when applied to cardiac computed tomography
[23] and using a multi-electrode ECGI sock intraoperatively [24]. ECGI has also been successfully combined,
by our group, with CMR in patients amyloidosis [25]
and arrhythmogenic cardiomyopathy [26]. It is with
this method that we can detect subtle EP abnormalities
that are often missed by conventional 12-lead ECG [27].
The challenge for the cardiologist is identifying whether
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Fig. 1 MyoFit46 study flowchart. BP, Blood pressure; CMR, cardiac magnetic resonance imaging; ECG, electrocardiogram; GP, general practitioner;
MRI, magnetic resonance imaging; REDCap, research electronic data capture; PACS, picture archiving and communication system

subtle EP abnormalities, which are more prevalent in the
ageing myocardium, will put an individual at higher risk
of sudden cardiac death or not [28]. In order to bridge

this knowledge gap, ECGI will allow us to link regional
EP aberrations with myocardial substrate changes for
mechanistic insights into the aetiology of arrythmias.
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Table 2 Overview of clinically significant reportable CMR findings
Category

Pathology

Ventricular structure

Moderate-severe LV hypertrophy

Ventricular function

Moderate-severe LV impairment
Moderate-severe RV impairment

Atrial size

Moderate-severe atrial dilation

Valvular pathology

Structural valve abnormalities e.g. bicuspid aortic valve
Moderate-severe valvular stenosis
Moderate-severe valvular regurgitation

Pericardial effusion

Moderate-severe pericardial effusion
Cardiac tamponade

Shunts

Ventricular septal defect
Atrial septal defect

Cardiac masses

LV thrombus
Intracardiac mass
Valvular mass e.g. vegetation/fibroelastoma

Myocardial inflammation

Acute/chronic myocardial inflammation

Myocardial infarction

Acute/chronic myocardial infarction

Myocardial fibrosis

Clinically significant LGE

Perfusion defects

Clinically significant inducible perfusion defects

Extra cardiac findings

Other suspected, significant or life-threatening finding

LGE, Late gadolinium enhancement; LV, left ventricle; RV, right ventricle

Our pipeline will enable reconstruction of epicardial surface biopotentials projected onto the cardiac geometry
using inverse solution mathematics to measure epicardial
activation and repolarization parameters which can then
be spatially correlated with myocardial tissue characteristics derived by CMR. [29].
We recently developed a re-usable and dry-electrodebased CMR-compatible vest to permit high-throughput
ECGI research and seamless integration with CMR (up
to 3 Tesla [T]). This was achieved in collaboration with
textile engineers at the École Nationale Supérieure des
Arts et Industries Textiles (ENSAIT, Roubaix, France)
and with g.Tec medical engineering GmbH (Schiedlberg,
Austria). The technology consists of two matching washresilient and reusable garments: one embedded with 256
dry electrodes (the electrode vest) and the other (the
CMR-safe marker vest) embedded with co-registered
fiducial markers (Beekley medical, Bristol, Connecticut).
The signal from each electrode is collected and amplified
using the HIamp 256 bundle GT-8016/USBamp GT-0216
and processed for analysis in specially designed software,
g.Recorder (g.Tec).
Prior to CMR, the participant will wear the electrode
vest which is secured onto the chest using adjustable fasteners. Body surface potentials will be measured from
all electrodes at a sampling frequency of 2400 Hz for
5 min at rest, in the supine position. The electrode vest
is then removed leaving only the marker vest which the

participant wears inside the CMR scanner. Accurate electro-anatomical mapping of ECGI and CMR data will then
be achieved through an initial 4 mm contiguous-slice
transaxial black-blood thoracic stack for marker co-registration. Our ECGI workflow is summarized in Fig. 2.
CMR
Outline

Imaging will be performed on a 3 T [200 × 80mT/m/s x
mT/m] MRI system (Magnetom Prisma, Serial Number
166032, Siemens, 60 cm bore) operating VE11C-SP01,
with an 18-channel phased-array chest coil and spine
array (up to 24-elements) equipped with Gadgetron
[30] (Linux box, 24 cores). Participants will be scanned
using a protocol which combines standard and advanced
CMR imaging techniques and is designed to be completed within a 45 min scanning session. Standardized
CMR protocols have been described in detail previously
[31, 32]. Brachial and non-invasive central BP assessment using a Cardioscope II BP + device (USCOM, Sydney, Australia; cuff on the right arm) will be performed
at baseline in the scanner bore, prior to the scan starting, followed by resting, peak stress (during adenosine
administration) and recovery measurements, also inside
the scanner bore. Continuous digital pulse oximeter
monitoring will be obtained throughout using the Nonin
7500FO fiber optic MRI table-top pulse oximeter (Nonin,
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Fig. 2 High-throughput reusable ECGI vest for CMR. A The garment is embedded with 256 uniformly distributed dry electrodes that connect to
g.HIamp for the recordings. B To ensure good skin contact of the dry electrodes an inflatable gilet is worn over the electrode vest for the duration
of the recordings. This design allows for rapid montage onto and off the chest. After the recording is complete the inflatable jacket and electrode
vest are removed leaving only the marker vest that the participant then wears into the CMR scanner. ECGI, electrocardiographic imaging. Other
abbreviations as in Fig. 1

Plymouth, USA). The CMR protocol is outlined in Fig. 3
and MR sequence details summarized in Table 3.
Cardiac structure and function

Initial CMR scout imaging will include sagittal, coronal
and transverse piloting of the chest in single heartbeat,
free-breathing, acquisitions. This will be followed by a

thin contiguously sliced transaxial set of turbo spin echo
(TSE) images (4 mm thickness no gap) across the chest
(approximately 90 slices) using a half-Fourier acquisition single-shot turbo spin echo (HASTE) sequence.
These T2 weighted, dark blood, images will localize the
fiducial markers on the ECGI vest and facilitate co-registration during post processing. Local 2
 nd order cardiac

Fig. 3 MyoFit46 CMR protocol. 2/3/4CH, 2/3/4 chamber; 4D, 4-dimensional; Ao, aorta; AVLAX, aortic valve long axis; AVSAX, aortic valve short axis;
ECV, extracellular volume; HASTE, half-fourier single-shot turbo spin-echo; LGE, late gadolinium enhancement; LVLAX, left ventricular long axis;
LVSAX, left ventricular short axis
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Table 3 MyoFit46 CMR sequence parameters
Description

LV short axis
cine*

Native and
post GBCA T1
map

Native T2 map Aortic flow

LGE

4D flow

Pulse sequence Dark blood TSE Cine imaging
HASTE
bSSFP

bSSFP, MOCO,
single shot
MOLLI

bSSFP, MOCO
single shot

Gradient echo bSSFP, MOCO,
phase contrast single shot
cine

Bright blood
MOCO bSSFP
with PSIR

3D Spoiled
gradient echo
(WIP CS785B)

Flip angle (°)

160.0

50.0

20.0

TR/data acqui‑
sition window
(ms)

251

29.1/–

–/167

70.0

20.0

50.0

50.0

15

–/148

9.24/–

144.0/70

–/203

39.76

TE (ms)

81.0/4.04

1.25/2.9

GRAPPA factor
(parallel imag‑
ing)

2

2

1.12/2.7

1.26/2.86

2.46/4.6

1.04/2.53

1.01/2.83

2.26/5.0

2

2

2

3 (T-PAT)

2

7.6 (CS)

Slice gap (mm) 0.0
Default field of
View (mm)

490 × 398

2.0

12.0

NA

NA

~ 100

2.0

0.0

380 × 285

360 × 270

360 × 270

380 × 214

360 × 270

360 × 270

400 × 310

Matrix size

256 × 135

256 × 140

256 × 144

192 × 120

192 × 97

192 × 111

256 × 144

160 × 102

1

30

1

1

1

1

1

20

ECG triggering/ PT
gating

RG

PT

PT

RG

PT

PT

RG

Free breathing
or breath hold

BH

BH

BH

BH

FB

FB

FB

FB (± navi‑
gated)

Orientation
(slices) [PE
direction]

Transverse
(×110) [AP]

SA view
base to apex
(approxi‑
mately × 12)
[AP]

SA (×3 base,
Mid SA [AP]
mid, apex) [AP]

Transverse at
level of the
PA bifurcation
[AP]

SA (×3 base,
SA view
mid, apex) [AP] base to apex
(approxi‑
mately × 9)
[AP]

Reconstructed
voxel size
Calculated
cardiac phases

Transverse
anatomy

1.9 × 1.9 × 4.0

1.5 × 1.5 × 8.0

1.4 × 1.4 × 8.0

1.9 × 1.9 × 8.0

2.0 × 2.0 × 6.0

Perfusion

1.9 × 1.9 × 8.0

1.4 × 1.4 × 8.0

2.5 × 2.5 × 2.5

Sagittal [AP]

2-D, 2-dimensional; AP, antero-posterior; BH, breath hold; bSSFP, balanced steady-state free precession; CS, compressed sensing; FB, free breathing; GRAPPA,
generalized auto-calibrating partially parallel acquisitions; HASTE, half-fourier single-shot turbo spin-echo; MOCO, motion-corrected; MOLLI, modified look-locker
inversion recovery; PE, phase encoding; PSIR, phase sensitive inversion recovery; PT, prospectively triggered; RG, retrospectively gated; RL, right left; SA, short axis; TE,
echo time; TPAT, temporal parallel imaging; TR, temporal resolution; TSE, turbo spin echo. Other abbreviations as in Table 2
*LV SAX cine stack is 8 mm slice thickness

shimming will be prescribed onto HASTE data and automatically copied to the rest of our protocolled sequences.
To assess left ventricular (LV) structure and function we
will acquire three long axis cines (vertical long axis, horizontal long axis and left ventricular outflow tract) and an
LV short axis cine stack (SAX) using breath-held ECG
retro-gated balanced steady state free precession (bSSFP)
imaging. To assess right ventricular (RV) structure and
function we will acquire RV outflow tract (sagittal and
oblique-sagittal planes) and vertical RV long-axis bSSFP
cines. For more detailed aortic valve (AV) assessment
we will acquire coronal LV outflow tract (LVOT) and AV
short axis bSSFP cines.
Tissue characterization

The native myocardial T
 1 time, before the administration
of gadolinium based contrast agent (GBCA), can lengthen
even in the absence of late gadolinium enhancement
(LGE) and it is this ability to detect so-called ‘subclinical’

fibrosis that will make it particularly useful for our analysis of myocardial resilience in old age [33, 34]. In order to
obtain native T
 1 maps we will acquire breath-held single
shot bSSFP motion-corrected (MOCO) modified LookLocker inversion recovery (MOLLI) images using prototype 5 s(3 s)3 s, at the basal, mid and apical LVSAX levels,
with volume selective magnetic field strength (B0) shimming, in diastole [35, 36]. Standard deviation (SD) maps
will be automatically generated and used to cross check
the reliability of corresponding MOLLI T1 values in coregistered regions of interest, aiming for a SD of < 40 ms.
A description of this technique has been outlined elsewhere [37].
To create extracellular volume (ECV) maps we will perform two co-registered T
 1 mapping acquisitions: before
and approximately 10 min after infusion of the second
dose of GBCA (Dotarem, Gadoterate meglumine, Guerbet, France) using MOLLI prototypes 5 s(3 s)3 s) and
4 s(1 s)3 s(1 s)2 s respectively, at the basal, mid and apical
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LVSAX slice. We will then generate pixel-wise ECV maps
by determining the ratio of the change in T1 values, following correction for blood cell density (using validated
point-of-care hematocrit readings) [31, 38, 39]. This will
be done by transposing regions of interest (ROIs) in the
septal midwall (or alternative remote myocardial zone)
and blood pool from native onto the post-GBCA 
T1
maps. Two types of ECV maps will be generated per participant for cross-validation: (1) A synthetic ECV map,
which will be generated directly from the scanner using
a synthetic hematocrit derived from native T1 values, as
described previously [39]; (2) A conventional ECV map,
which will be generated at the end of each scan using the
measured blood hematocrit (derived from the hemoglobin value obtained from point of care testing).
We will perform single-slice breath-held T
 2 mapping
using a MOCO single shot bSSFP sequence at the level of
the mid LV short axis and prior to GBCA administration.
Aortic flow imaging

With advancing age, biochemical, histological and blood
flow changes in the main arteries result in wall stiffening
[40]. Arterial stiffness has traditionally been measured in
peripheral vessels due to ease of access, even though aortic stiffness is a stronger prognostic marker because of its
resultant increase in LV afterload and wider downstream
end-organ damage [41]. To analyze the effects of aortic
stiffening in older age we will measure local aortic distensibility (derived from aortic area measurements) and
regional pulse wave velocity (PWV) across the ascending
aorta and aortic arch. Both regional and local measurements of aortic stiffness capture variation in aortic tissue
composition across its course, but have different sensitivities to pathology related to arterial stiffening and are
associated with different cardiovascular outcomes [42].
In order to obtain measurements of aortic length, we will
initially acquire an ECG-gated, free-breathing sagittal
cine of the aorta (‘candy cane’ view). This image will then
serve as a localizer to pilot blood-flow velocity maps at
the level of the bifurcation of the main pulmonary artery
transecting the ascending and descending thoracic aorta.
We will use a high temporal resolution phase-contrast
free-breathing ECG-gated gradient echo sequence as previously described [31, 32, 43] (imaging parameters provided in Table 3). Aortic flow imaging will be performed
at baseline and repeated during peak stress (immediately
before the stress perfusion acquisition) alongside simultaneous pressure waveform and pulse oximetry measurements. An outline of the methods used to derive pulse
wave velocity is summarized in Fig. 4. Measurements
of flow velocity and pressure waveforms will be used to
derive wave intensity, wave separation, reservoir pressure
and reflection magnitude as previously described [44].
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Stress perfusion imaging

For myocardial ischemia evaluation we will perform
stress perfusion imaging using adenosine on all participants using a dual-cannula approach (typically sited
in the antecubital fossae) which has been previously
described [45]. Intravenous adenosine will be infused
peripherally at 140 µg/kg/min from one of the cannulas for a minimum of 3 min and a maximum of 4 min
to achieve an adequate response (assessed through a
HR increment of 10 beats per minute and/or the development of symptoms). A higher dose of 175 µg/kg/min
may be infused for a further 2 min in the event of limited symptoms or failure to increment HR by a minimum of 10 beats per minute. The first dose of Dotarem
(0.05 mmol/kg) will be injected via the other canula at
a rate of 4 mL/second along with 20 mL of saline. The
adenosine infusion will be stopped during the first pass
perfusion image acquisition which will be acquired using
a free-breathing MOCO saturation-recovery bSSFP
sequence to cover 3 LVSAX slices across every heartbeat.
Approximately 10 min following peak stress, rest perfusion imaging (using the same sequences described above)
will then be completed without adenosine, using the second dose of Dotarem.
Late gadolinium enhancement

To assess the presence of LGE we will acquire an LVSAX
stack of conventional (‘bright-blood’) LGE images using a
free-breathing MOCO bSSFP sequence with phase-sensitive inversion-recovery (PSIR) [46]. LGE acquisitions
will commence approximately 5 min after the second
dose of Dotarem.
4‑Dimensional flow

Four-dimensional (4-D) intracavitary flow CMR provides
comprehensive hemodynamic flow assessments, taking
into account the multidirectional and multidimensional
nature of blood flow through the cardiac chambers [47]
with the potential to improve our understanding of the
ageing cardiovascular phenotype. We will compare the
use of respiratory-navigated vs. free-breathing retrospectively ECG-gated, spoiled gradient echo sequences
(work-in-progress CS785B, Siemens Healthineers, Erlangen, Germany), with field of view covering the LVOT,
proximal aorta, and all 4 cardiac chambers. The acquisition will be performed at the end of the CMR protocol
with GBCA on board to allow for improved blood myocardial contrast. Sequence parameters based on the published literature [48] are provided in Table 3.
Quality assurance

Normal values for key CMR biomarkers collected in
MyoFit46 will be generated from healthy volunteer
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Fig. 4 Measuring aortic pulse wave velocity (PWV). A Free breathing gradient echo phase contrast cine of the ascending aorta at the level of the
pulmonary artery bifurcation. B Aortic ‘candy cane’ used to pilot the aortic flow. Points 4 and 12 are highlighted to show the linear plane used for
transection and for measuring 3D distance using our dedicated software. C Flow wave curves of both the ascending and descending aorta after
normalization for peak flow which are used to measure the transit time. D PWV (m/s) is then calculated as 3D distance divided by transit time. 3D,
3-dimensional; PWV, pulse wave velocity

datasets acquired using the same sequences on the same
magnet system. The upper and lower range of normal
values will be defined as the mean ± 1.96 standard deviations from the normal data, according to standardized
recommendations [38].
Prior to commencing native myocardial T
1 mapping in MyoFit46, two quality assurance steps will be
implemented.
A quality assurance phantom testing protocol for T1,
T2 and ECV mapping will be undertaken to verify the
stability of our magnet-sequence combination over time
and throughout the project lifecycle. We will use the
medical-device grade T
 1 mapping and ECV standardization (T1MES) phantom [49] (field-strength specific for

3 T with regulatory clearance from the Food and Drug
Administration and Conformité Européene-marking)
as well as the T2 Phantom [50] (field-strength agnostic).
Both devices have been previously developed by our
group in collaboration with Resonance Health (Perth,
Australia) and with the US and German National Metrology Institutes (National Institute of Standards and
Technology and Physikalisch-Technische Bundesantalt
respectively) [49, 51]. At study start and study close both
phantoms (stored in the temperature-controlled MRI
scanner environment) will be interrogated by flip angle
maps and be scanned using slow overnight inversion
recovery spin echo (IRSE) and multi-echo SE, to establish reference T1 and T2 values. At study start, study close
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and once every 2 months between these timepoints, the
T1 MES phantom will additionally be scanned in accordance with the T1MES user manual [51, 52] using the fat/
water sequence for field maps and using 3 repeats of the
MOLLI 5 s(3 s)3 s and 4 s(1 s)3 s(1 s)2 s prototypes. At
study start, study close and once every 2 months between
these timepoints, the T2 phantom will additionally be
scanned using the fat/water sequence and three repeats
of the T2 mapping sequence. Phantom body temperature will be recorded prior to the start of each scan session, aiming for an ambient CMR room temperature of
21–22 °C. A schematic of our phantom-based quality
assurance framework for MyoFit46 is presented in Fig. 5.

with 10% erosion from the blood myocardial boundary and divided according to the 16-segment American
Heart Association (AHA) model. On the native and postGBCA MOLLI T
 1 maps, a ROI will be drawn in the mid
septum and co-registered with automatically generated
pixel-wise SD maps. Semiautomated LGE quantification
will be carried out using a 2 SD and a 5 SD approach following manual selection of an ROI in an area of remote/
dark myocardium [36, 56]. We will also use the full width
half maximum technique [57] for comparison against the
other methods. Segments with LGE will be annotated to
allow for subsequent interpretation of the mapping data
[54].

Imaging pipelines and analyses

Aortic flow analysis

Primary imaging analyses
Imaging pipelines

Proximal ascending and descending thoracic aortic contours will be traced semi-automatically using validated
software (ArtFun, INSERM U678, Paris, France) to derive
flow-velocity waveforms [43, 58]. Aortic distensibility
will be measured at local, specified regions of the aorta
and calculated according to established methods [43, 59].
PWV over the upper thoracic aorta will be measured
using length and transit time (from derived aortic velocity profiles) [43].

All CMR image DICOMs (Digital Imaging and Communications in Medicine), derived results and associated ROIs will be stored on a customized web-based
server running XNAT 1.6.5 and hosted at UCL. DICOMcompliant imaging format will be used for all MRI data
including raw list mode data and images that have been
reconstructed on the scanner using the Gadgetron framework. CMR data will be analyzed using Circle Cardiovascular Imaging, cvi [42] version 5.3.2 (Calgary, Canada).
CMR analysis

Standardized CMR image interpretation and post-processing will be performed as previously described [31,
32, 53, 54]. Briefly, analyses will include volumetric measurements of the 4 cardiac chambers (using manual epicardial and endocardial contour tracings), assessment
of biventricular and valvular function, analysis of native
myocardial T1 and T2, stress perfusion imaging and LGE
assessment. Papillary muscles and trabecular tissue will
be consistently included in the LV mass measurements,
as previously described [53, 54]. Left ventricular volumetric and maximal wall thickness analyses will additionally be performed using the previously validated
openCARE artificial intelligence (AI) analysis platform.
This platform has already been shown to have improved
precision when compared to human observers in independent studies [55].
A standard operating procedure has been developed
for the manual analysis of LGE, 
T1, T2 and ECV by
trained researchers. For T
 1, T2 and ECV analysis, epicardial and endocardial contours will be drawn manually

4‑Dimensional flow analysis

Intracavitary 4-D flow CMR will allow us to derive
parameters such as turbulent kinetic energy, wall shear
stress, PWV and variations in LV vortices [47, 60]. For
example, previous studies have shown that there is an
inverse relationship between LV diastolic vortices [61]
and ageing and that turbulent kinetic energy could be a
promising subclinical marker of LV dysfunction [62].
4-D flow CMR also allows for detailed valve quantification with particularly promising results in mitral regurgitation, since it allows for direct quantification of flow
at the level of the valve which remains valid even in the
presence of other valvular lesions or shunts [63]. These
markers of intracavitary hemodynamics will be used
to characterize pathophysiological responses to ageing
beyond conventional methods of flow. 4-D flow image
post-processing will be performed using CAAS (PIE
Medical Imaging, Maastricht, The Netherlands). During analysis we will ensure that any contours drawn in
the magnitude images are cross-referenced with velocity images to take into account large movements and the
effects of partial volume. Velocity data will be encoded
into individual vectors, allowing us to assess local

(See figure on next page.)
Fig. 5 T1 and T2 Phantom QA framework. The same imaging protocol (defined here) is used for QA of multi-parametric T1 and T2 mapping data
during the project lifecycle. Sequences in black are performed at baseline and then repeated every 8 weeks. Sequences in grey are performed
at baseline and then for a total of 2 per year. 3D, 3-dimensional; FA, flip angle; IRSE, inversion recovery spin echo; MOLLI, modified Look-Locker
inversion recovery; QA, quality assurance; SSFP, steady-state free precession
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patterns of flow such as vortices, visualize and quantify
wall shear stress and study kinetic energy [64].
ECGI analysis

Body surface ECGs collected by g.Recorder will be stored
and analyzed offline using previously established methods [18, 25, 26]. Signal averaging will be performed using
in-house, customized, software (Matlab, MathWorks,
Natick, MA) to enhance the quality of the signals from
body surface potentials. The location of the fiducial markers on the torso corresponding to the electrode positions
will be combined with the heart-torso geometry obtained
from the CMR HASTE stack and reconstructed to create
epicardial meshes using commercially available software
(Amira, ThermoFisher, MA, USA, version 2020.3). Unipolar epicardial electrograms will then be reconstructed
by solving the inverse problem in collaboration with the
Rudy laboratory [19, 26]. Generated epicardial maps
will enable calculation of epicardial activation and repolarization times and corresponding isochrone maps will
be generated for visualization. These maps will be used
to identify discrete areas of abnormal electrophysiology
and correlated with matching substrate abnormalities
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detected by CMR. An exemplar pilot isochrone map that
we have created using this CMR-ECGI pipeline is reproduced in Fig. 6. At scale validation of the co-registration
process with CMR has not been performed before and in
order to address this we will carry out test–retest reproducibility and intra-/inter-observer variability studies. All
raw and post-processed ECGI data will be stored securely
in the project-specific UCL XNAT repository.
Cardiac computational modelling

In order to extend our multi-dimensional deep phenotyping of the ageing heart we will perform advanced
cardiac computational modelling in collaboration with
the Barcelona Supercomputing center (Barcelona,
Spain). Using the established ‘Alya Red’ [65] supercomputer driven data modelling protocol [65–67], we
will combine epicardial electrophysiological data (from
ECGI) with the rich myocardial structural, functional,
perfusion and flow data obtained from CMR to create
personalized electro-mechanical-flow whole-heart simulations per participant [68].

Fig. 6 ECGI analysis workflow. A ECGI data is collected by g.Recorder software. B CMR image showing one transverse slice of the HASTE used to
segment the epicardium. Note the fiducial MRI markers (white) situated on the anterior and posterior torso. C Ventricular segmentation of the same
participant’s HASTE data, showing heart torso geometry and markers (Beekley medical, Bristol, Connecticut) following volume rendering, landmark
localization and segmentation in Amira software (ThermoFisher, MA, USA, version 2020.3). D Signal averaging is performed using in house,
customized software (Matlab, MathWorks, Natick, MA) and unipolar electrograms are then combined with Amira software heart torso geometry by
solving the inverse problem of ECGI in collaboration with the Rudi laboratory. E Activation time isochrone maps in disease highlighting an area of
fractionation corresponding to an area of LGE/scar in the mid anteroseptum of the left ventricle. EGM, electrogram. Other abbreviations as in Figs. 1,
2 and 3
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Study analysis Plan
Statistical analysis

Both overt and subclinical cardiovascular disease biomarkers (binary or continuous variables, such as LV
ejection fraction, native T
 1, ECV, LGE, etc.) will be determined through this proposed CMR-ECGI deep phenotyping protocol and such biomarkers will serve as either
outcome or predictor variables in the various analyses
planned. On the one hand, MyoFit46 will unravel how
key exposures during early-, mid- and later life (e.g. environmental pollution, communicable disease exposure,
socioeconomic status, etc.) interact with traditional cardiovascular risk factors (e.g. smoking, obesity, alcohol
intake, etc.) and multimorbidity to determine cardiovascular disease (outcome) in older age. On the other hand,
we will also prospectively study the association between
discovered cardiovascular disease biomarkers (predictors) and key outcomes of interest ascertained during
long-term follow-up of the birth cohort participants (e.g.
functional status or major adverse cardiovascular events
such as hospital admissions, nonfatal stroke, myocardial
infarction, cardiovascular death, etc.).
Since several of our exposures of interest are either
categorical or represent trajectories/time-varying exposures; associations between exposures and outcomes will
be analyzed using a range of statistical approaches relevant for life course data [69–71]. Associations between
trajectories of exposures and cardiovascular disease biomarkers will be analyzed using latent growth curve analysis [71]. In order to subsequently link with outcomes we
will use a two-step process as previously described [72].
We will use structural equation models using full information maximum likelihood to account for missing data
in NSHD under missing at random assumptions.
Sample size estimates have been calculated to permit
detection of a small effect size (Cohen’s f2 = 0.03) using
multivariable regression analysis. A sample size of 533
achieves 80% power to detect an f2 ≥ 0.030 attributable
to up to 9 independent variable(s) using an F-Test with
a significance level (alpha) of 0.050. For categorical outcomes a logistic regression of a binary response variable
on a continuous, normally distributed variable with a
sample size of 533 observations achieves 92% power at a
0.05 significance level to detect a change corresponding
to an odds ratio of 1.5.
Data sharing

A data sharing policy will be published and managed
through MRC Slylark website (https://skylark.ucl.ac.uk/
Skylark) including access to research publications, talks
presented at international conferences and links to academic social media accounts. Raw data will be archived
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for a minimum of 10 years within the UCL open XNAT
server (https://ucl-open-xnat.cs.ucl.ac.uk/app/template/
Login.vm#!) and these data will be shared with bona fide
researchers along with the relevant clinical and demographic metadata that will be archived in REDCap. CMR
and ECGI standard operating procedures will be electronically archived alongside the data, and as hard copies.
Software pipelines will be stored in electronic lab books,
including software version numbers.

Discussion
MyoFit46 aims to combine the rich life course data of
the NSHD with cutting-edge CMR and ECGI technologies and multi-dimensional cardiac simulations to provide new insights into the long-term myocardial sequelae
of key exposures from birth. Uniquely the NSHD provides us with detailed, prospectively collected data since
birth, allowing us to study the individual, combined and
cumulative impacts of risk factors, and their mediators
on myocardial health by older age. Previous older age
cohorts have carried out CMR imaging, but none have
performed CMR-ECGI integration with stress perfusion,
multi-parametric mapping, and 4-D intracardiac flow
as is being proposed here. ECGI will enable us to correlate overt and subclinical markers of arrhythmogenesis
with CMR-derived structural and functional abnormalities. By merging these complex structural, functional,
hemodynamic and electrophysiological data into cardiac
computational models we be deepening our understanding of the ageing myocardium, representing a world first
in terms of CMR-driven personalized care. We expect
our results to impact public health by identifying novel
risk factors for cardiovascular disease and addressing
the growing challenge of multi-morbidity with the aim
of maintaining myocardial health into older age for the
benefit of humanity globally.
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